Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Parra-Ruiz

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica|May 1, 2012
[Safety and efficacy of daptomycin therapy in older adults with pluripathology]Jorge Parra-Ruiz, José Hernández-Quero
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|January 11, 2013
[Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone]Jorge Parra-Ruiz, José Hernández-Quero
The Journal of Infection|January 2, 2016
Vancomycin does not remain appropriate empiric therapy in coagulase-negative staphylococcal bacteremiaNieves M Coronado-Álvarez, Jorge Parra-Ruiz
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
Diagnostic Microbiology and Infectious Disease|October 25, 2011
In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycinCéline Vidaillac, Jorge Parra-Ruiz, Michael Joseph Rybak
The Journal of Rheumatology|July 15, 2003
Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazidJorge Parra Ruiz, Norberto Ortego Centeno, Enrique Raya Alvarez
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|June 17, 2018
Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocciNieves M Coronado-Álvarez, Diego Parra, Jorge Parra-Ruiz
International Journal of Antimicrobial Agents|July 19, 2011
In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolatesCeline Vidaillac, Jorge Parra-Ruiz, Patricia Winterfield, et al.
Antimicrobial Agents and Chemotherapy|August 11, 2010
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilmJorge Parra-Ruiz, Celine Vidaillac, Warren E Rose, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 3, 2009
[Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment]Jorge Parra-Ruiz, Cristina Tomas-Jiménez, Leopoldo Muñoz-Medina, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Enfermedades Infecciosas Y Microbiologia Clinica|May 1, 2012
[Safety and efficacy of daptomycin therapy in older adults with pluripathology]Jorge Parra-Ruiz, José Hernández-Quero
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|January 11, 2013
[Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone]Jorge Parra-Ruiz, José Hernández-Quero
The Journal of Infection|January 2, 2016
Vancomycin does not remain appropriate empiric therapy in coagulase-negative staphylococcal bacteremiaNieves M Coronado-Álvarez, Jorge Parra-Ruiz
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
Diagnostic Microbiology and Infectious Disease|October 25, 2011
In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycinCéline Vidaillac, Jorge Parra-Ruiz, Michael Joseph Rybak
The Journal of Rheumatology|July 15, 2003
Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazidJorge Parra Ruiz, Norberto Ortego Centeno, Enrique Raya Alvarez
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|June 17, 2018
Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocciNieves M Coronado-Álvarez, Diego Parra, Jorge Parra-Ruiz
International Journal of Antimicrobial Agents|July 19, 2011
In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolatesCeline Vidaillac, Jorge Parra-Ruiz, Patricia Winterfield, et al.
Antimicrobial Agents and Chemotherapy|August 11, 2010
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilmJorge Parra-Ruiz, Celine Vidaillac, Warren E Rose, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 3, 2009
[Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment]Jorge Parra-Ruiz, Cristina Tomas-Jiménez, Leopoldo Muñoz-Medina, et al.
Pageof 3